{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:27Z","timestamp":1793018127419,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)","id":[{"id":"https:\/\/ror.org\/00f2yqf98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell redirecting therapies (TCRTs), including Chimeric antigen receptor (CAR)-T cells and T-cell engagers (TCEs), are emerging as transformative treatments for autoimmune diseases. However, clinical application is currently restricted to specialized centers, leaving most clinicians with limited first-hand experience. We aimed to assess the knowledge, perception, and barriers regarding TCRTs among German rheumatologists. A prospective, web-based survey was distributed to German rheumatologists via congresses and digital channels from September 2024 through January 2025. Drafting the design and reporting of the survey results was performed regarding international recommendations as the \u201cchecklist for reporting results of internet e-surveys\u201d (CHERRIES). Statistical analysis was conducted with SPSS. Of 98 participants (median age 43\u00a0years) the majority was based at university hospitals (46.3%) and 94.8% were willing to refer patients to specialized centers. However, respondents considered only 5% of their patients suitable for TCRT, primarily those with severe, refractory connective tissue diseases. The main barriers cited were high costs (82%), limited clinical experience (65.5%) and applicability in only a limited number of patients (35.4%). Knowledge of side effects (e.g., cytokine release syndrome, infections, hypogammaglobulinemia) and contraindications (e.g. heart failure, chronic infections) was generally accurate. Yet, the self-appraisal of existing knowledge on TCRT was only seen as medium by the questioned rheumatologists (median of 4.86, on a 0 to 10 scale with 10 is best knowledge). Participating German rheumatologists demonstrated a high willingness to refer patients for TCRTs and appeared to possess good safety knowledge. However, the therapy is currently viewed as a niche option for highly active, refractory cases, with costs and limited data serving as primary barriers to broader implementation.<\/jats:p>","DOI":"10.1007\/s00296-026-06300-3","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:50:39Z","timestamp":1790423439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rheumatologists\u2019 expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8517-616X","authenticated-orcid":false,"given":"Anna","family":"Meinecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9192-4026","authenticated-orcid":false,"given":"Johannes","family":"Knitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-6759","authenticated-orcid":false,"given":"Thorben","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7442-2570","authenticated-orcid":false,"given":"Judith","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9697-276X","authenticated-orcid":false,"given":"Felix","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2601-8203","authenticated-orcid":false,"given":"Christina","family":"D\u00fcsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-3415","authenticated-orcid":false,"given":"Marco","family":"Zeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5135","authenticated-orcid":false,"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-1384","authenticated-orcid":false,"given":"Melanie","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-6838","authenticated-orcid":false,"given":"Isabell","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-6728","authenticated-orcid":false,"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Working Group Young Rheumatologists of the German society for Rheumatology and Immunology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"6300_CR1","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1016\/j.ymthe.2024.07.028","volume":"32","author":"GSF Anderson","year":"2024","unstructured":"Anderson GSF, Chapman MA (2024) T cell-redirecting therapies in hematological malignancies: current developments and novel strategies for improved targeting. Mol Ther 32:2856\u20132891. https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.028","journal-title":"Mol Ther"},{"key":"6300_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169","journal-title":"N Engl J Med"},{"key":"6300_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2018","unstructured":"Guedan S, Calderon H, Posey ADJ, Maus MV (2018) Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev 12:145\u2013156. https:\/\/doi.org\/10.1016\/j.omtm.2018.12.009","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6300_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A L\u00f6ffler","year":"2003","unstructured":"L\u00f6ffler A, Gruen M, Wuchter C et al (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia 17:900\u2013909. https:\/\/doi.org\/10.1038\/sj.leu.2402890","journal-title":"Leukemia"},{"key":"6300_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"6300_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.31547\/bct-2023-028","volume":"6","author":"J Pan","year":"2023","unstructured":"Pan J (2023) Chimeric antigen receptor T cell therapy for acute leukemia. Blood Cell Ther 6:145\u2013150. https:\/\/doi.org\/10.31547\/bct-2023-028","journal-title":"Blood Cell Ther"},{"key":"6300_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101615","volume":"5","author":"C Zhang","year":"2024","unstructured":"Zhang C, Sun Y, Yi D et al (2024) Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE\/CTONG2104). Cell Rep Med 5:101615. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101615","journal-title":"Cell Rep Med"},{"key":"6300_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC et al (2025) Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 393:349\u2013361. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"key":"6300_CR9","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMc2506740","volume":"393","author":"L Bucci","year":"2025","unstructured":"Bucci L, B\u00f6ltz S, Hagen M et al (2025) BCMA T-cell engager therapy in patients with refractory autoimmune disease. N Engl J Med 393:1544\u20131547. https:\/\/doi.org\/10.1056\/NEJMc2506740","journal-title":"N Engl J Med"},{"key":"6300_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK et al (2024) CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5:550-558.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002","journal-title":"Med"},{"key":"6300_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S et al (2024) BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med 391:867\u2013869. https:\/\/doi.org\/10.1056\/NEJMc2408786","journal-title":"N Engl J Med"},{"key":"6300_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L et al (2024) CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"issue":"5","key":"6300_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ard.2025.10.026","volume":"85","author":"AN St\u00fctz","year":"2025","unstructured":"St\u00fctz AN, Lahu L, Jaschinski S et al (2025) Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis. Ann Rheum Dis 85(5):958\u2013961. https:\/\/doi.org\/10.1016\/j.ard.2025.10.026","journal-title":"Ann Rheum Dis"},{"key":"6300_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630569","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Su S (2025) CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives. Front Immunol 16:1630569. https:\/\/doi.org\/10.3389\/fimmu.2025.1630569","journal-title":"Front Immunol"},{"key":"6300_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1747777","volume":"17","author":"J Li","year":"2026","unstructured":"Li J, Guo Q, Li L, Wang J, Zhang L (2026) CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. Front Immunol 17:1747777. https:\/\/doi.org\/10.3389\/fimmu.2026.1747777","journal-title":"Front Immunol"},{"key":"6300_CR16","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G (2004) Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 6:e34. https:\/\/doi.org\/10.2196\/jmir.6.3.e34","journal-title":"J Med Internet Res"},{"key":"6300_CR17","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e403","volume":"38","author":"O Zimba","year":"2023","unstructured":"Zimba O, Gasparyan AY (2023) Designing, conducting, and reporting survey studies: a primer for researchers. J Korean Med Sci 38:e403. https:\/\/doi.org\/10.3346\/jkms.2023.38.e403","journal-title":"J Korean Med Sci"},{"key":"6300_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/COC.0000000000000596","volume":"42","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Ali FS et al (2019) Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy. Am J Clin Oncol 42:789\u2013796. https:\/\/doi.org\/10.1097\/COC.0000000000000596","journal-title":"Am J Clin Oncol"},{"key":"6300_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924208","volume":"12","author":"L Chen","year":"2022","unstructured":"Chen L, Li Y, Zhang Z et al (2022) Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis. Front Oncol 12:924208. https:\/\/doi.org\/10.3389\/fonc.2022.924208","journal-title":"Front Oncol"},{"key":"6300_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.37157","volume":"7","author":"VG Zaha","year":"2024","unstructured":"Zaha VG (2024) Insights into cardiovascular risks of chimeric antigen receptor T-cell therapy-from peril to promise. JAMA Netw Open 7:e2437157. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37157","journal-title":"JAMA Netw Open"},{"key":"6300_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos F-X, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot J-M (2024) Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer 205:114075. https:\/\/doi.org\/10.1016\/j.ejca.2024.114075","journal-title":"Eur J Cancer"},{"key":"6300_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T et al (2024) Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med 30:1593\u20131601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1","journal-title":"Nat Med"},{"key":"6300_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander T, Kr\u00f6nke J, Cheng Q, Keller U, Kr\u00f6nke G (2024) Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med 391:864\u2013866. https:\/\/doi.org\/10.1056\/NEJMc2407150","journal-title":"N Engl J Med"},{"key":"6300_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82:1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"6300_CR25","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","volume":"64","author":"I Haase","year":"2025","unstructured":"Haase I, Richter J, Holzer M et al (2025) A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review. Rheumatology (Oxford) 64:5101\u20135107. https:\/\/doi.org\/10.1093\/rheumatology\/keaf190","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"6300_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2025.11.027","volume":"84","author":"V Keitel","year":"2025","unstructured":"Keitel V, Kreissl MC, Goetze T et al (2025) CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. J Hepatol 84(4):829\u2013836. https:\/\/doi.org\/10.1016\/j.jhep.2025.11.027","journal-title":"J Hepatol"},{"key":"6300_CR27","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou I, Wilhelm A, Albach F et al (2025) Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis 84:e4\u2013e7. https:\/\/doi.org\/10.1016\/j.ard.2025.01.008","journal-title":"Ann Rheum Dis"},{"key":"6300_CR28","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P (2023) Rheumatoid arthritis. Lancet 402:2019\u20132033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","journal-title":"Lancet"},{"key":"6300_CR29","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/rheumatology\/keae096","volume":"63","author":"A Neves","year":"2024","unstructured":"Neves A, Viveiros L, Venturelli V, Isenberg DA (2024) Where are we now in biologic drugs for myositis? Rheumatology (Oxford) 63:2938\u20132947. https:\/\/doi.org\/10.1093\/rheumatology\/keae096","journal-title":"Rheumatology (Oxford)"},{"key":"6300_CR30","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd AGS, Lilleker JB, Amin T et al (2022) British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 61:1760\u20131768. https:\/\/doi.org\/10.1093\/rheumatology\/keac115","journal-title":"Rheumatology (Oxford)"},{"key":"6300_CR31","doi-asserted-by":"publisher","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","volume":"28","author":"SJ Keating","year":"2022","unstructured":"Keating SJ, Gu T, Jun MP, McBride A (2022) Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transpl Cell Ther 28:404.e1-404.e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.021","journal-title":"Transpl Cell Ther"},{"key":"6300_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-3-030-94353-0_37","volume-title":"The EBMT\/EHA CAR-T cell handbook","author":"E McGrath","year":"2022","unstructured":"McGrath E, Machalik P (2022) The regulatory framework for CAR-T cells in Europe: current status and foreseeable changes AND centre qualification by competent authorities and manufacturers. In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (eds) The EBMT\/EHA CAR-T cell handbook. Springer International Publishing, Cham, pp 191\u2013198. https:\/\/doi.org\/10.1007\/978-3-030-94353-0_37"},{"key":"6300_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"key":"6300_CR34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN et al (2024) T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 30:984\u2013989. https:\/\/doi.org\/10.1038\/s41591-024-02826-w","journal-title":"Nat Med"},{"key":"6300_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE et al (2025) Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail 31:415\u2013455. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045","journal-title":"J Card Fail"},{"key":"6300_CR36","doi-asserted-by":"publisher","first-page":"e2461683","DOI":"10.1001\/jamanetworkopen.2024.61683","volume":"8","author":"L Camacho-Arteaga","year":"2025","unstructured":"Camacho-Arteaga L, Iacoboni G, Kwon M et al (2025) Late adverse events after chimeric antigen receptor T-cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma. JAMA Netw Open 8:e2461683. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.61683","journal-title":"JAMA Netw Open"},{"key":"6300_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ajh.26259","volume":"96","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Ederhy S, Ezine E et al (2021) Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study. Am J Hematol 96:1101\u20131111. https:\/\/doi.org\/10.1002\/ajh.26259","journal-title":"Am J Hematol"},{"key":"6300_CR38","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T et al (2024) Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med 390:2047\u20132060. https:\/\/doi.org\/10.1056\/NEJMoa2401361","journal-title":"N Engl J Med"},{"key":"6300_CR39","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39:3978\u20133992. https:\/\/doi.org\/10.1200\/JCO.21.01992","journal-title":"J Clin Oncol"},{"key":"6300_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMra2314005","volume":"392","author":"J Henter","year":"2025","unstructured":"Henter J (2025) Hemophagocytic lymphohistiocytosis. N Engl J Med 392:584\u2013598. https:\/\/doi.org\/10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"issue":"23","key":"6300_CR41","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1158\/1078-0432.CCR-25-1513","volume":"31","author":"T Sato","year":"2025","unstructured":"Sato T, Butler MO, Piperno-Neumann S et al (2025) Incidence and management of adverse events associated with tebentafusp treatment in metastatic uveal melanoma: pooled safety analysis of 410 patients. Clin Cancer Res 31(23):5027\u20135036. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1513","journal-title":"Clin Cancer Res"},{"key":"6300_CR42","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM et al (2024) Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer 12:e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518","journal-title":"J Immunother Cancer"},{"key":"6300_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102991","volume":"139","author":"ZM Za\u00efr","year":"2025","unstructured":"Za\u00efr ZM, Butterworth G, Shalaby M, O\u0161tarija\u0161 E, Thisthlethwaite F (2025) T-cell engager toxicity in clinical phase trials; a systematic review and meta-analysis. Cancer Treat Rev 139:102991. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102991","journal-title":"Cancer Treat Rev"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06300-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:23Z","timestamp":1793016383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06300-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6300"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06300-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests relevant to the study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A formal enquiry was submitted to the ethics committee of the Philipps University Marburg, Germany (24\u2013224 ANZ). Due to the anonymous and non-interventional nature of the study, it was deemed as exempted from IRB review. Participation was voluntary. This manuscript does not contain human or animal studies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"With participation, rheumatologists gave consent for publication of the anonymous survey results.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"264"}}